By Dr. Leeds, osteopathic physician and deprescribing specialist.
Why do patients need medication for opioid withdrawal symptoms?
If you have never experienced opioid withdrawal, you may want to consider having some sympathy for those who have. Words cannot express how difficult it is to get through the days of withdrawal sickness, and it can take weeks for the last of the symptoms to fade.
Opioid withdrawal is rarely dangerous by itself, yet it is so unpleasant that few people get through it without help. So, doctors prescribe comfort medications that take the edge off of the symptoms, and for decades that medication has been clonidine. Lucemyra arrived in 2018 as the first non-opioid drug approved specifically for the job.
Patients ask me about the two drugs often, usually in the same words that brought you here. Lucemyra vs clonidine: which one is best for opioid withdrawal, or opiate withdrawal, as many people still call it? Does the expensive one earn its price? And, if you are tapering off of Suboxone, do you need either one at all?
What is clonidine?
Clonidine, or Catapres, is a blood pressure medication. The Catapres label lists a single indication, the treatment of hypertension, yet doctors have prescribed it for opioid withdrawal for decades without the FDA ever approving it for that purpose. This is off-label prescribing, and it is legal, common, and often good medicine.
How does a blood pressure pill help with withdrawal? Clonidine is an alpha-2 adrenergic agonist, meaning that it stimulates a receptor that acts as a brake on the release of norepinephrine, a close cousin of adrenaline. When opioids leave the body, that brake fails, and the adrenaline system runs wide open.
The sweating, the racing pulse, the anxiety, the runny nose, and the goosebumps are all the adrenaline system with nothing holding it back. Clonidine puts a foot back on the brake, and it remains the comfort medication that most patients coming off of opioids are handed first.
What is Lucemyra?
Lucemyra, or lofexidine, is in the same family as clonidine. The FDA approved it in 2018 for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, which makes it the one non-opioid drug with an approval for opioid withdrawal.
When I first wrote this article in 2019, Lucemyra was the new drug. In 2026, it is still called the new drug, mostly by the people selling it.
The label is more modest than the marketing. Lucemyra is approved for up to 14 days, with the dosing guided by symptoms and a gradual reduction over two to four days at the end, and it says in plain words that Lucemyra is not a treatment for opioid use disorder. That last line is the one to remember, because Lucemyra is a comfort medication for the withdrawal period and nothing more, and so is clonidine.
How are the two drugs different?
Both are central alpha-2 agonists, and they do the same thing to the same receptor. In fact, there is no special withdrawal receptor that one drug hits and the other misses, whatever a sales sheet may imply.
The difference is in what else the drug does. Clonidine lowers blood pressure very well, and the drop can be steep in a person who is already dehydrated from vomiting and diarrhea. The explanation usually offered for Lucemyra’s milder effect on blood pressure is a difference in how the two drugs act at a related receptor, the alpha-1 receptor, but the laboratory studies do not agree on that, and the FDA’s own review of Lucemyra found that it binds both receptors much as clonidine does. What is settled is the clinical finding: in the trials that compared them, lofexidine lowered blood pressure less than clonidine, and that fits what I see in patients.
Doctors know about the blood pressure problem, so they hold clonidine to small doses spaced six to eight hours apart and cap the daily total, and patients have told me many times that it felt as if the drug would have helped more if they had been allowed to take it more often. Lucemyra may be taken four times a day at five- to six-hour intervals, so the coverage is steadier. While that is a real advantage, it is a modest one, and low blood pressure, slow pulse, and fainting are still Lucemyra’s first warning.
Which drug works better for withdrawal symptoms?
In my experience, the two relieve withdrawal symptoms about equally well. Yet, the trials that earned Lucemyra its approval compared it with a placebo, not with clonidine, so the label makes no claim that it works better than the old drug, and I would not make that claim either.
Neither drug treats cravings. I am not aware of any study that shows otherwise, and I would be surprised by one, because cravings come from the empty opioid receptor, and these drugs never go near it. So, neither one can replace buprenorphine, the medicine in Suboxone, which sits on the opioid receptor and quiets the withdrawal and the craving together.
An analogy that might help is a car alarm. Imagine an alarm that goes off whenever the car is bumped. Opioid withdrawal is the alarm blaring after the opioid is gone, and clonidine and Lucemyra are a pair of earmuffs.
While this is not a perfect analogy, it explains why comfort medications feel like partial relief and buprenorphine feels like the problem has gone away. Buprenorphine deals with the sensor itself, and if your goal is to stay off of heroin or fentanyl for good, you want the sensor handled.
What are the side effects and warnings?
The two drugs share a side effect list: low blood pressure, slow pulse, dizziness, drowsiness, and dry mouth. The Catapres label puts dry mouth at about 40 of every 100 patients and drowsiness at about 33 of 100, and Lucemyra’s most common reactions are the same. So, you will not escape the dizziness by paying more.
While the lists overlap, Lucemyra has two warnings of its own. It prolongs the QT interval, an electrical measurement on the electrocardiogram, so it is to be avoided in congenital long QT syndrome and used with ECG monitoring in people with electrolyte problems, heart failure, slow heart rhythms, liver or kidney impairment, or other QT-prolonging drugs, methadone among them. And, it adds to the sedation caused by benzodiazepines, alcohol, and other sedating drugs.
Interestingly, the Lucemyra label lists no contraindications at all. Liver or kidney impairment calls for a lower dose, not avoidance, and you may read elsewhere that the drug is forbidden in liver disease or in anyone with a rhythm history. The label does not say that.
Both drugs must be stopped gradually, since stopping clonidine suddenly can cause agitation, headache, and a rapid rise in blood pressure. Both labels say to reduce the dose over two to four days, so your doctor should write the short taper into the prescription from the start.
Is Lucemyra worth the extra cost?
Surprisingly, the fact that clonidine is so old is its greatest advantage. There is no patent, the generics are very inexpensive, and decades of use mean there are few unknown dangers left to discover. It has stood the test of time.
Lucemyra is a brand-name drug, and although the FDA approved the first generic lofexidine in 2024, insurance plans often still want a prior authorization before they will cover it, which some doctors will fight through and some will not. If a patient cannot afford a drug, it cannot help them. That sentence was true when I first wrote it, and it is still the center of this comparison.
Of course, many doctors prefer to prescribe only what the FDA has approved for the purpose, and I understand the instinct. Yet, clonidine has been easing opioid withdrawal off-label for longer than some of those doctors have been in practice, and there is nothing careless about using it.
In my opinion, for most patients quitting heroin, fentanyl, oxycodone, or a similar opioid, clonidine will be adequate and very nearly as effective as Lucemyra, at a tiny fraction of the cost. Lucemyra earns its price when low blood pressure limits how much clonidine a patient can take, when a patient has done poorly on clonidine before, or when the prescribing doctor will only write for an on-label drug. Both have a place, and having a choice is a good thing.
Do you need clonidine or Lucemyra during a Suboxone taper?
This is an excellent question, and it is the one that people tapering off of Suboxone, or any buprenorphine medication, ZubSolv included, ask me most. The search that brings most of them here is clonidine for Suboxone withdrawal, and the honest answer is that most of them should not need either drug, if the taper is done right.
Suboxone, or buprenorphine, holds on to the opioid receptor and does not let go. Withdrawal after each dose reduction tracks how much of the receptor the drug is still covering, and that relationship is not a straight line. At higher doses, a cut removes very little coverage, while at the lowest doses, the same cut removes a great deal, which is why the last part of a Suboxone taper is so much harder than the first part, and why so many patients park at a small dose for years.
The fix is not a second drug. The fix is smaller cuts, in proportion to the dose you are taking now, with a hold whenever your body tells you that the last cut was too much. Deprescribers call this a hyperbolic taper, and I believe it is the right way to come off of any drug that causes physical dependence.
Going back to the car alarm, a slow taper is rolling the car forward an inch at a time, and the sensor never trips. Comfort medications are for the moments when the alarm goes off anyway: the final drop-off from the last tiny dose, a taper that must be fast for some outside reason, or an abstinence-based detox with no buprenorphine in the picture at all. I have written separately about using Lucemyra to get off of Suboxone, and it can help at the tail. So, ask for smaller cuts before you ask for a second drug, because a taper that needs one every week is going too fast.
Buprenorphine dependence is a real physical dependence, and it is not addiction. Physical dependence is a medical condition, and the treatment for a medical condition is a medical taper. Your doctor must slow the taper when it is too fast, and you and your doctor may agree to go a bit faster when it is going well, as tolerated.
The most dangerous week is the one after withdrawal ends.
There is a warning on the Lucemyra label that belongs on every page about opioid withdrawal. A person who completes opioid discontinuation is likely to have a reduced tolerance to opioids, and if they use again, they are at increased risk of a fatal overdose. The label tells doctors to say this to patients and to the people who care for them, so I am saying it here.
The dose that was ordinary a month ago can be deadly after two weeks off. While this is true whether the withdrawal was eased by clonidine, by Lucemyra, or by nothing at all, it is the strongest argument I know for buprenorphine treatment over withdrawal alone.
If you go through withdrawal anyway, keep naloxone, or Narcan, in the house, and make sure the people around you know where it is and how to use it, since the nasal spray has been sold without a prescription since 2023. And, if an abstinence-based program plans to start you on naltrexone or Vivitrol afterward, tell the doctor there which comfort medication you took, because Lucemyra may reduce the effect of oral naltrexone.
Never hesitate to call 911 for anyone who is unresponsive or barely breathing. And, withdrawal itself is a reason to go to the emergency room if you cannot keep fluids down, because dehydration is the one part of opioid withdrawal that can truly hurt you.
So, which one should you ask your doctor for?
Ask the question, and let the answer come out of a conversation with the doctor who knows your blood pressure, your heart rhythm, your kidneys, and your insurance. If clonidine is what is offered, you are not being shortchanged. If Lucemyra is offered and covered, there is nothing wrong with taking the better-tolerated drug.
Opioid withdrawal is terrible, and it is temporary. You do not have to get through it alone.
Comfort medications are the exception in Dr. Leeds’ practice, not the plan.
Dr. Leeds treats opioid dependence with buprenorphine by telemedicine for patients throughout Florida, and the same principle runs through every Suboxone taper in the practice: the smaller the cut, the less there is to cover. Whether a comfort medication is needed at the tail of a taper is decided patient by patient, never in place of slowing a taper that is going too fast. Tapers are gradual and patient directed, with weekly video visits and text access in between.
To ask whether buprenorphine treatment or a slower taper is right for you, contact Dr. Leeds through the contact form.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.
